Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published June 2014
  • Article
  • Info & Metrics
  • PDF
Loading

Tumor Targeting with Integrin αvβ3 and MMP-2

Crisp et al. Page 1514

Better detection and treatment of cancer needs improved targeting and delivery of imaging and therapeutic agents to tumors. In this report by Crisp and colleagues, MMP-2/9-activatable cell-penetrating peptides have been conjugated with an αvβ3-binding domain, cyclic-RGD. In vivo, such dual targeting produced highly increased tumor fluorescence compared with an untargeted peptide, and enhanced depth penetration. Dually targeting the chemotherapeutic monomethylauristatin E improved the drug's efficacy in mammary MDA-MB-231 orthotopic human and syngeneic Py230 murine models with significant tumor regression and survival. This novel strategy could be useful in optical tumor imaging and chemotherapeutic delivery.

Hec-1 Inhibitor against Breast Cancer

Huang et al. Page 1419

NDC80/Hec1 is part of the kinetochore complex and is overexpressed in human cancers. In this study, Huang and colleagues explore the potential of the novel pharmacokinetically improved Hec1-targeted compound TAI-95 in breast cancer. Nine out of eleven breast cancer cell lines tested, including multidrug-resistant cell lines, were shown to be sensitive to nanomolar concentrations of TAI-95 in vitro. Moreover, oral administration of TAI-95 significantly inhibited breast tumor growth in vivo. TAI-95 was also shown to downregulate P-glycoprotein and increase the potency of cytotoxic P-glycoprotein substrates. This study highlights the potential of TAI-95 as a novel drug in breast cancer treatment.

Discovery of a Covalent EGFR Mutant Selective Inhibitor

Tjin Tham Sjin et al. Page 1468

There is a clinical need to identify next generation EGFR tyrosine kinase inhibitors (TKI) that can overcome clinically arising drug-resistant EGFRT790M mutations while sparing wild-type EGFR (EGFRWT) to avoid on-target toxicity. Here, Tjin Tham Sjin and colleagues describe the in vitro and in vivo characterization of EGFR mutant-selective irreversible diaminopyrimidine inhibitors that have low affinity for EGFRWT. The lead compound potently inhibits EGFRT790M, both in vitro and in vivo, but more importantly spares EGFRWT. Such a compound offers superiority over first and second generation EGFR TKIs and is showing promising clinical activity with a 67% RECIST partial response rate with no dose-related signs of EGFRWT-associated toxicities.

Anetumab Ravtansine, a Novel Antibody–Drug Conjugate Targeting Mesothelin

Golfier and Kopitz et al. Page 1537

Anetumab ravtansine is an antibody–drug conjugate (ADC) consisting of anti-mesothelin antibody conjugated to DM4, a potent microtubule inhibitor. Here, Golfier, Kopitz and colleagues demonstrate its specific effect on proliferating mesothelin-positive cancer cells in vitro. Moreover, clinically relevant doses of anetumab ravtansine resulted in tumor eradication in several subcutaneous, orthotopic, and patient-derived xenograft models in vivo. Importantly, anetumab ravtansine demonstrated a killing bystander effect on neighboring mesothelin-negative tumor cells contributing to the antitumor activity of ADC. Anetumab ravtansine has potential to be efficacious in a wide variety of tumors and is currently in clinical evaluation.

  • ©2014 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 13 (6)
June 2014
Volume 13, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther June 1 2014 (13) (6) 1391;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther June 1 2014 (13) (6) 1391;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Tumor Targeting with Integrin αvβ3 and MMP-2
    • Hec-1 Inhibitor against Breast Cancer
    • Discovery of a Covalent EGFR Mutant Selective Inhibitor
    • Anetumab Ravtansine, a Novel Antibody–Drug Conjugate Targeting Mesothelin
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement